

Clean copy of amended specification paragraphs

Page 1, Cross Reference To Related Applications Section:

This application is a divisional of U.S. Application No. 09/366,981, filed on August 4, 1999, which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 60/140,962, filed on June 24, 1999.

Page 3, paragraph 3:

In yet another embodiment, the CRIF peptide comprises the sequence Phe-Ile-Asp-Pro-Glu-Leu-Gln-Arg-Ser-Trp-Glu-Glu-Lys-Glu-Gly-Glu-Gly-Val-Leu-Met-Pro-Glu (SEQ ID NO:1).

Page 3, paragraph 4:

In yet another embodiment, the CRIF peptide comprises the sequence Phe-Ile-Asp-Pro-Glu-Leu-Gln-Arg-Ser-Trp-Glu-Glu-Thr-Glu-Gly-Glu-Glu-Gly-Gly-Leu-Met-Pro-Glu (SEQ ID NO:2).

Page 3, paragraph 5:

In another embodiment, the CRIF peptide comprises the sequence Glu-Gly-Glu-Gly-Val-Leu-Met-Pro-Glu (SEQ ID NO:3).

Page 3, paragraph 6:

In a further embodiment, the CRIF peptide comprises the sequence Leu-Met-Pro-Glu (SEQ ID NO:4).

Page 3, paragraph 8:

In another embodiment, the CRIF peptide comprises the sequence Leu-Ala-Asp-Pro-Lys-Ala-Gln-Arg-Ser-Trp-Glu-Glu-Glu-Glu-Glu-Glu-Glu-Glu-Arg-Glu-Glu-Asp-Leu-Met-Pro-Glu (SEQ ID NO:5).

Pages 6 and 7, spanning paragraph:

The invention should be construed to include any and all CRIF peptides comprising amino acid lengths which range from at least three contiguous amino acids to as much as twenty two amino acids in length, being positioned within the rat prepro-TRH 178-199 molecule. The CRIF peptide of the invention may therefore comprise at least three contiguous amino acids in length, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, at least nineteen, at least twenty, at least twenty one, and up to twenty two contiguous amino acids in length, wherein the peptide is positioned within the rat prepro-TRH 178-199 molecule. Preferably, the CRIF peptide of the invention comprises either four or nine amino acids in length. Preferred rodent CRIF sequence include from three to twenty two contiguous amino acid sequences of the sequence Phe-Ile-Asp-Pro-Glu-Leu-Gln-Arg-Ser-Trp-Glu-Glu-Lys-Glu-Gly-Glu-Gly-Val-Leu-Met-Pro-Glu (full length rat CRIF; SEQ ID NO:1) and the sequence Phe-Ile-Asp-Pro-Glu-Leu-Gln-Arg-Ser-Trp-Glu-Glu-Thr-Glu-Gly-Glu-Glu-Gly-Gly-Leu-Met-Pro-Glu (full length mouse CRIF; SEQ ID NO:2), and also the sequence Glu-Gly-Glu-Gly-Val-Leu-Met-Pro-Glu (a rat CRIF peptide; SEQ ID NO:3), the sequence Leu-Met-Pro-Glu (another rat CRIF peptide; SEQ ID NO:4), and any derivatives and analogs thereof which retain the biological activity of CRIF as defined herein.

Page 8, paragraph 1:

A preferred human CRIF is a peptide having from three to twenty six contiguous amino acids of the sequence Leu-Ala-Asp-Pro-Lys-Ala-Gln-Arg-Ser-Trp-Glu-Glu-Glu-Glu-Glu-Glu-Glu-Glu-Arg-Glu-Glu-Asp-Leu-Met-Pro-Glu (full length human CRIF; SEQ ID NO:5).